A Global, Phase 3, Open-Label, Single Arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 Mg (Triptorelin Mesylate Injection, 11.25 Mg) in Patients with Advanced Prostate Cancer (KATANA E3M)
Latest Information Update: 14 Feb 2025
Price :
$35 *
At a glance
- Drugs Triptorelin (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms KATANA E3M
- Sponsors Foresee Pharmaceuticals
- 10 Feb 2025 According to Foresee Pharmaceuticals media release, data from this trial will presented at American Society of Clinical Oncology, Genitourinary (ASCO-GU) Cancers Symposium conference
- 31 Jan 2025 New trial record